Patients nutrional status: BMI and serum albumin a predictive indcator of survival in patients with metastatic breast cancer
Association of Breast Surgery ePoster Library. Courtney D. 05/15/17; 166277; P067
Dr. Donald Courtney
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Rate & Comment (0)
As many as 20-30%(1) of breast cancer patients develop metastasis. Despite recent treatment advances and earlier detection, median survival approaches 2 years(2).Nutritional status and serum albumin levels in patients prior to cancer surgery has been investigated with higher levels of serum albumin associated with improved outcome (3). We investigate how serum albumin levels and patient BMI act a predictor of survival in patients with metastatic breast cancer.
Methods:
Data was collected on all breast cancer patients who developed metastases while undergoing treatment or surveillance at tertiary referral breast centre between 2000-2016.Clinicopathological details including site of primary and metastatic tumour were recorded. The serum albumin and BMI on the date of diagnosis was recorded and the overall survival of each patient was calculated. A Kaplan Meier and log rank test was performed to assess length of survival.
Results:
The age (median (range)) was 55.2 (27.9-87.2). Of the cohort 209(n=209) developed metastasis after primary diagnosis with median disease free interval of 30 months. The median length of survival post diagnosis of metastatic disease was 13.7 (0.28- 122(months).Patients who were underweight(BMI<18.5) with low serum albumin (<35mg/mmol) were shown to impact length of survival ((mean (SE)) 11.3 months (7.8)) when compared to normal levels (28.8 months (3.3)).This was shown to be statistically significant (p=0.01).
Conclusion
Patient nutritional status has shown to have an impact on the length of patient survival. Accurate recording and interpretation of serum albumin and nutritional assessment at time of diagnosis in those patients who develop metastatic breast cancer may serve to optimise patient management and survival.
Methods:
Data was collected on all breast cancer patients who developed metastases while undergoing treatment or surveillance at tertiary referral breast centre between 2000-2016.Clinicopathological details including site of primary and metastatic tumour were recorded. The serum albumin and BMI on the date of diagnosis was recorded and the overall survival of each patient was calculated. A Kaplan Meier and log rank test was performed to assess length of survival.
Results:
The age (median (range)) was 55.2 (27.9-87.2). Of the cohort 209(n=209) developed metastasis after primary diagnosis with median disease free interval of 30 months. The median length of survival post diagnosis of metastatic disease was 13.7 (0.28- 122(months).Patients who were underweight(BMI<18.5) with low serum albumin (<35mg/mmol) were shown to impact length of survival ((mean (SE)) 11.3 months (7.8)) when compared to normal levels (28.8 months (3.3)).This was shown to be statistically significant (p=0.01).
Conclusion
Patient nutritional status has shown to have an impact on the length of patient survival. Accurate recording and interpretation of serum albumin and nutritional assessment at time of diagnosis in those patients who develop metastatic breast cancer may serve to optimise patient management and survival.
As many as 20-30%(1) of breast cancer patients develop metastasis. Despite recent treatment advances and earlier detection, median survival approaches 2 years(2).Nutritional status and serum albumin levels in patients prior to cancer surgery has been investigated with higher levels of serum albumin associated with improved outcome (3). We investigate how serum albumin levels and patient BMI act a predictor of survival in patients with metastatic breast cancer.
Methods:
Data was collected on all breast cancer patients who developed metastases while undergoing treatment or surveillance at tertiary referral breast centre between 2000-2016.Clinicopathological details including site of primary and metastatic tumour were recorded. The serum albumin and BMI on the date of diagnosis was recorded and the overall survival of each patient was calculated. A Kaplan Meier and log rank test was performed to assess length of survival.
Results:
The age (median (range)) was 55.2 (27.9-87.2). Of the cohort 209(n=209) developed metastasis after primary diagnosis with median disease free interval of 30 months. The median length of survival post diagnosis of metastatic disease was 13.7 (0.28- 122(months).Patients who were underweight(BMI<18.5) with low serum albumin (<35mg/mmol) were shown to impact length of survival ((mean (SE)) 11.3 months (7.8)) when compared to normal levels (28.8 months (3.3)).This was shown to be statistically significant (p=0.01).
Conclusion
Patient nutritional status has shown to have an impact on the length of patient survival. Accurate recording and interpretation of serum albumin and nutritional assessment at time of diagnosis in those patients who develop metastatic breast cancer may serve to optimise patient management and survival.
Methods:
Data was collected on all breast cancer patients who developed metastases while undergoing treatment or surveillance at tertiary referral breast centre between 2000-2016.Clinicopathological details including site of primary and metastatic tumour were recorded. The serum albumin and BMI on the date of diagnosis was recorded and the overall survival of each patient was calculated. A Kaplan Meier and log rank test was performed to assess length of survival.
Results:
The age (median (range)) was 55.2 (27.9-87.2). Of the cohort 209(n=209) developed metastasis after primary diagnosis with median disease free interval of 30 months. The median length of survival post diagnosis of metastatic disease was 13.7 (0.28- 122(months).Patients who were underweight(BMI<18.5) with low serum albumin (<35mg/mmol) were shown to impact length of survival ((mean (SE)) 11.3 months (7.8)) when compared to normal levels (28.8 months (3.3)).This was shown to be statistically significant (p=0.01).
Conclusion
Patient nutritional status has shown to have an impact on the length of patient survival. Accurate recording and interpretation of serum albumin and nutritional assessment at time of diagnosis in those patients who develop metastatic breast cancer may serve to optimise patient management and survival.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}